| Size | Price | |
|---|---|---|
| 100g | ||
| Other Sizes |
| Targets |
3-Hydroxyanisole targets MAO-A (monoamine oxidase A) as an inhibitor, with an IC50 of 24 ± 2.8 μM. MAO-A is an enzyme that catalyzes the oxidative deamination of monoamine neurotransmitters such as serotonin, norepinephrine, and dopamine. By inhibiting MAO-A, 3-hydroxyanisole may increase the levels of these neurotransmitters. It can be used to study neurological and psychiatric diseases.
|
|---|---|
| ln Vitro |
In vitro, 3-hydroxyanisole has inhibitory activity against MAO-A with an IC50 of 24 ± 2.8 μM. The compound's ability to inhibit MAO-A has been characterized in enzyme assays using purified MAO-A or tissue homogenates. Its activity as a phenolic compound has been studied in various biochemical assays. The compound is a severe eye irritant.
|
| ln Vivo |
In vivo, 3-hydroxyanisole is systemically absorbed and disrupts the function of the liver, kidneys, central nervous system, and redox processes. It increases levels of Hb, red blood cells, and white blood cells. The compound causes flaccid paralysis without anesthesia, tremor, and muscle contraction or spasticity in oral lethal-dose studies of mice and rats. It can be used to study neurological and psychiatric diseases.
|
| Enzyme Assay |
In non-cell-based enzyme assays, 3-hydroxyanisole's inhibition of MAO-A is evaluated using biochemical methods. Purified MAO-A enzyme or tissue homogenates (such as rat brain mitochondria) are incubated with a substrate (such as kynuramine or serotonin) and varying concentrations of 3-hydroxyanisole. The enzymatic activity is measured by monitoring the production of metabolites using spectrophotometric or fluorometric methods, and IC50 values are determined from inhibition curves.
|
| Cell Assay |
In vitro cellular assays for 3-hydroxyanisole involve testing its effects on cultured cells. The compound's inhibition of MAO-A may be assessed in cells expressing the enzyme. Its cytotoxicity and effects on neurotransmitter levels may be evaluated in neuronal cell lines. The compound's effects on cell viability and oxidative stress may also be assessed. However, specific cellular assay data are limited in publicly available sources.
|
| Animal Protocol |
In vivo animal studies for 3-hydroxyanisole have been conducted to assess its toxicity and effects on the nervous system. The compound is typically administered via oral routes. It causes flaccid paralysis without anesthesia, tremor, and muscle contraction or spasticity in oral lethal-dose studies of mice and rats. It disrupts the function of the liver, kidneys, central nervous system, and redox processes.
|
| ADME/Pharmacokinetics |
3-Hydroxyanisole has a molecular weight of 124.14 and a molecular formula of C7H8O2. It is a phenolic compound. The compound has inhibitory activity against MAO-A with an IC50 of 24 ± 2.8 μM. It is a severe eye irritant. The compound is typically stored as a powder at -20°C for long-term stability.
|
| Toxicity/Toxicokinetics |
Toxicity Data
LC50 (Rat) = 11,500 mg/m³/4 hours 3-Hydroxyanisole is a severe eye irritant and causes flaccid paralysis in oral lethal-dose studies of mice and rats. It is systemically absorbed and disrupts the function of the liver, kidneys, central nervous system, and redox processes. The compound should be handled with appropriate safety precautions, including the use of personal protective equipment. It should be stored and handled in accordance with standard laboratory safety guidelines. |
| Additional Infomation |
3-Methoxyphenol belongs to the phenolic class of compounds, with a methoxy substituent at the 3-position in its molecular structure. It is both a phenolic compound and a monomethoxybenzene compound. Its function is similar to that of resorcinol. It has been reported that 3-methoxyphenol is found in Sedum species, buckwheat, and other organisms with relevant data.
3-Hydroxyanisole (3-Methoxyphenol) is a phenolic compound with inhibitory activity against MAO-A (IC50 = 24 ± 2.8 μM). It can be used to study neurological and psychiatric diseases. The compound is a severe eye irritant and causes flaccid paralysis in oral lethal-dose studies of mice and rats. 3-Hydroxyanisole is not an approved drug and is intended for research use only. |
| Molecular Formula |
C7H8O
|
|---|---|
| Molecular Weight |
124.14
|
| Exact Mass |
124.052
|
| CAS # |
150-19-6
|
| PubChem CID |
9007
|
| Appearance |
Colorless to light pink liquid（Density：1.131 g/cm3）
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
244.3±0.0 °C at 760 mmHg
|
| Melting Point |
-17 °C
|
| Flash Point |
119.1±4.8 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.535
|
| LogP |
1.51
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
9
|
| Complexity |
83
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])[H])C1=C([H])C([H])=C([H])C(=C1[H])O[H]
|
| InChi Key |
ASHGTJPOSUFTGB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H8O2/c1-9-7-4-2-3-6(8)5-7/h2-5,8H,1H3
|
| Chemical Name |
3-Methoxyphenol
|
| Synonyms |
NSC-21735 NSC21735NSC 217353-Hydroxyanisole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.0554 mL | 40.2771 mL | 80.5542 mL | |
| 5 mM | 1.6111 mL | 8.0554 mL | 16.1108 mL | |
| 10 mM | 0.8055 mL | 4.0277 mL | 8.0554 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00752102 | COMPLETEDWITH RESULTS | Drug: Calcitriol (Rocaltrol®) Drug: Paricalcitol |
Chronic Kidney Disease Coronary Calcification Disorders of Calcium and Bone Metabolism Vitamin D Deficiency |
Joslin Diabetes Center | 2008-09 | Phase 4 |
| NCT06467812 | RECRUITING | Dietary Supplement: Salt Tablets Dietary Supplement: Electrolyte Solution |
Healthy | National Aeronautics and Space Administration (NASA) | 2022-04-01 | Not Applicable |
| NCT00302952 | TERMINATEDWITH RESULTS | Drug: Lovastatin Drug: Placebo |
Rheumatoid Arthritis | National Institute of Allergy and Infectious Diseases (NIAID) | 2007-11-06 | Phase 2 |
| NCT02286921 | COMPLETEDWITH RESULTS | Drug: Testosterone cypionate Drug: Enzalutamide Drug: Testosterone Enanthate |
Castration Resistant Metastatic Prostate Cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-01 | Phase 2 |
| NCT04363164 | RECRUITING | Drug: Testosterone cypionate Drug: Enzalutamide Drug: Testosterone enanthate |
Castration Resistant Metastatic Prostate Cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2020-08-19 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
